Combined Resection Liver Metastases and Peritoneal Metastases

  • Arie Ariche
  • Dan Aderka
  • Almog Ben-Yaacov
  • Aviram Nissan


The liver and the peritoneum are two common sites for metastatic cancer spread. When there is isolated cancer spread to either of these organs, surgical resection of the metastatic disease has led to a significant improvement in the overall and disease-free survival both in selected patients compared to systemic chemotherapy alone which was previously the standard of care. At the same time, it is not uncommon for peritoneal metastases (PM) and liver metastases (LM) to occur synchronously. In patients undergoing resection of LM from various primary sites, chiefly colorectal LM, PM may be an incidental finding during the preoperative workup or during the surgical exploration itself. Similarly, in patients with PM being treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), one or more LM may be detected on preoperative imaging. Though the presence of two sites of metastases was initially a contraindication for a curative approach at either site, reports of surgical resection resulting in survival benefit have led to an adoption of this strategy for selected patients with LM and PM. Current evidence to support this approach comes from small retrospective studies; further evaluation in prospective studies is needed, and the selection criteria need to be better defined. Combined resection of LM and PM is performed for patients with metastases from colorectal cancer and epithelial ovarian cancer. Systemic therapy is used in most patients, and the role of intraperitoneal chemotherapy is less clear in these patients.


Liver metastases Peritoneal metastases Synchronous resection Combined resection of liver and peritoneal metastases HIPEC 


  1. 1.
    Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1452 patients and development of a prognostic model. Ann Surg. 2006;244(4):524–35. PubMedPubMedCentralGoogle Scholar
  2. 2.
    Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Jaeck D, Bachellier P, Guiguet M, et al. Long-term survival following resection of colorectal hepatic metastases: association Francaise de Chirurgie. Br J Surg. 1997;84:977–80.CrossRefPubMedGoogle Scholar
  4. 4.
    Adam R, Pascal G, Azoulay D, et al. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg. 2003;238:871–83.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19:59–71.CrossRefPubMedGoogle Scholar
  7. 7.
    Stangl R, Altendorf-Hofmann A, et al. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343:1405–10.CrossRefPubMedGoogle Scholar
  8. 8.
    Sugarbaker PH. Colorectal cancer: prevention and management of metastatic disease. Biomed Res Int. 2014;2014:Article ID 782890., 11 pp. Scholar
  9. 9.
    Otto G, Duber C, Hoppe-Lotichius M, et al. Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg. 2010;251:796–803.CrossRefPubMedGoogle Scholar
  10. 10.
    White RR, Avital I, Sofocleous CT, et al. Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointest Surg. 2007;11:256–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Wright AS, Sampson LA, Warner TF, et al. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology. 2005;236:132–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Dupuy DE. Microwave ablation compared with radiofrequency ablation in lung tissue-is microwave not just for popcorn anymore? Radiology. 2009;251:617–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbeck’s Arch Surg. 1999;384(6):576–87.CrossRefGoogle Scholar
  14. 14.
    Sugarbaker P, Bijelic L, Chang D, Yoo D, et al. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102(6):576–81.CrossRefPubMedGoogle Scholar
  15. 15.
    Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of North Central Cancer Treatment Group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Klaver YL, Simkens LH, Lemmens VE, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38:617–23.CrossRefPubMedGoogle Scholar
  17. 17.
    Lieu CH, Renfro LA, de Gramont A, et al. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol. 2014;32:2975–84.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kennecke H, Yu J, Gill S, et al. Effect of M1a and M1b category in metastatic colorectal cancer. Oncologist. 2014;19:720–6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sasaki Y, Hamaguchi T, Yamada Y, et al. Value of KRAS, BRAF, and PIK3CA mutations and survival benefit from systemic chemotherapy in colorectal peritoneal carcinomatosis. Asian Pac J Cancer Prev. 2016;17:539–43.CrossRefPubMedGoogle Scholar
  20. 20.
    Franko J, Shi Q, Meyers J, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(2):1709–19.CrossRefPubMedGoogle Scholar
  21. 21.
    Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.CrossRefPubMedGoogle Scholar
  22. 22.
    Elias D, Ouellet J-F, Bellon N, et al. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg. 2003;90:567–74. Scholar
  23. 23.
    Couinaud C. Le Foie. Etudes Anatomiques et Chirurgicales. Paris: Masson; 1957.Google Scholar
  24. 24.
    Elias D, Dube P, Bonvalot S, et al. Treatmentoflivermetastaseswithmoderate peritoneal carcinomatosis by hepatectomy and cytoreductive surgery followed by immediate post-operative intraperitoneal chemotherapy: feasibility and preliminary results. Hepato-Gastroenterology. 1999;46:360–3.PubMedGoogle Scholar
  25. 25.
    Carmignani CP, Ortega-Perez G, Sugarbaker PH. The management of synchronous peritoneal carcinomatosis and hematogenous metastasis from colorectal cancer. Eur J Surg Oncol. 2004;30:391–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Kianmanesh R, Scaringi S, Sabate J-M, et al. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg. 2007;245(4):597–603. Scholar
  27. 27.
    Aoki T, Umekita N, Tanaka S, Noda K, Warabi M, Kitamura M. Prognostic value of concomitant resection of extrahepatic disease in patients with liver metastases of colorectal origin. Surgery. 2008;143:706–14.CrossRefPubMedGoogle Scholar
  28. 28.
    Chua TC, Yan TD, Zhao J, et al. Peritoneal carcinomatosis and liver metastases from colorectal cancer treated with cytoreductive surgery perioperative intraperitoneal chemotherapy and liver resection. Eur J Surg Oncol. 2009;35:1299–305.CrossRefPubMedGoogle Scholar
  29. 29.
    Varban O, Levine EA, Stewart JH, et al. Outcomes associated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in colorectal cancer patients with peritoneal surface disease and hepatic metastases. Cancer. 2009;115:3427–36.CrossRefPubMedGoogle Scholar
  30. 30.
    Glockzin G, Renner P, Popp FC, Dahlke MH, von Breitenbuch P, Schlitt HJ, Piso P. Hepatobiliary procedures in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2011;18:1052–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Allard MA, Adam R, Ruiz A, Vibert E, Paule B, Levi F. Is unexpected peritoneal carcinomatosis still a contraindication for resection of colorectal liver metastases? Combined resection of colorectal liver metastases with peritoneal deposits discovered intra-operatively. Eur J Surg Oncol. 2013;39:981–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Maggiori L, Goéré D, Viana B, Tzanis D, Dumont F, Honoré C, Eveno C, Elias D. Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases be treated with a curative intent? A case-control study. Ann Surg. 2013;258:116–21.CrossRefPubMedGoogle Scholar
  33. 33.
    Alzahrani N, Ung L, Valle SJ, Ferguson J, Liauw W, Morris DL. Synchronous liver resection with cytoreductive surgery for the treatment of liver and peritoneal metastases from colon cancer: results from an Australian Centre. J Gastrointest Dig Syst. 2015;5:2.Google Scholar
  34. 34.
    Delhorme J-B, Dupont-Kazma L, Addeo P, Lefebvre F, Triki E, Romain B, Meyer N, Bachellier P, Rohr S, Brigand C. Peritoneal carcinomatosis with synchronous liver metastases from colorectal cancer: Who will benefit from complete cytoreductive surgery? Int J Surg. 2016;25:98–105.CrossRefPubMedGoogle Scholar
  35. 35.
    Navez J, Remue C, Leonard D, et al. Surgical treatment of colorectal cancer with peritoneal and liver metastases using combined liver and cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: report from a single-centre experience. Ann Surg Oncol. 2016;23:666–73.CrossRefPubMedGoogle Scholar
  36. 36.
    Lorimier G, Linot B, Paillocher N, Dupoiron D, Verrièle V, Wernert R, Hamy A, Capitain O. Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer. Eur J Surg Oncol. 2017;43:150–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Berger Y, Aycart S, Tabrizian P, Agmon Y, Mandeli J, Heskel M, Hiotis S, Sarpel U, Labow DM. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with liver involvement. J Surg Oncol. 2016;113:432–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Hadden WJ, de Reuver PR, Brown K, Mittal A, Samra JS, Hugh TJ. Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes. HPB (Oxford). 2016;18(3):209–20. CrossRefGoogle Scholar
  39. 39.
    Chua TC, Saxena A, Liauw W, Chu F, Morris DL. Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases–a systematic review. Eur J Cancer. 2012;48:1757–65.CrossRefPubMedGoogle Scholar
  40. 40.
    Hwang M, Jayakrishnan TT, Green DE, George B, Thomas JP, Groeschl RT. Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. Eur J Cancer. 2014;50:1747–57.CrossRefPubMedGoogle Scholar
  41. 41.
    de Cuba EMV, Kwakman R, Knol DL, Bonjer HJ, Meijer GA, Te Velde EA. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases. Systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev. 2013;39:321–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Elias D, Faron M, Goéré D, Dumont F, Honoré C, Boige V, Malka D, Ducreux MA. simple tumor load-based nomogram for surgery in patients with colorectal liver and peritoneal metastases. Ann Surg Oncol. 2014;21(6):2052–8. CrossRefPubMedGoogle Scholar
  43. 43.
    Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–57.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Feki A, Berardi P, Bellingan G, Major A, Krause KH, Petignat P, Zehra R, Pervaiz S, Irminger-Finger I. Dissemination of intraperitoneal ovarian cancer: discussion of mechanisms and demonstration of lymphatic spreading in ovarian cancer model. Crit Rev Oncol Hematol. 2009;72:1–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Pradeep S, Kim SW, SY W, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, SC O, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014;26:77–91.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Akin O, Sala E, Moskowitz CS, Ishill N, Soslow RA, Chi DS, Hricak H. Perihepatic metastases from ovarian cancer: sensitivity and specificity of CT for the detection of metastases with and those without liver parenchymal invasion. Radiology. 2008;248:511–7.CrossRefPubMedGoogle Scholar
  47. 47.
    Castadot P, Magne N, Berghmans T, Drowart A, Baeyens L, Smets D, Van Houtte P. Ovarian metastasis and lung adenocarcinoma: a case report. Cancer Radiother. 2005;9:183–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Lim MC, Kang S, Lee KS, Han SS, Park SJ, Seo SS, Park SY. The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol Oncol. 2009;112:28–34.CrossRefPubMedGoogle Scholar
  49. 49.
    Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW, Goodman BW, Merritt WM, Pircher TJ, Mikolajczyk SD, Nick AM, Celestino J, Eng C, Ellis LM, Deavers MT, Sood AK. A novel platform for detection of CK+ and CK CTCs. Cancer Discov. 2011;1:580–6.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Phillips KG, Velasco CR, Li J, Kolatkar A, Luttgen M, Bethel K, Duggan B, Kuhn P, McCarty OJ. Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient. Front Oncol. 2012;2:72.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Yeung T-L, Leung CS, Yip K-P, Au Yeung CL, Wong STC, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. a review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 2015;309(7):C444–56. Scholar
  52. 52.
    Prat J, FIGO Committee on Gynecologic Oncology. Abridged republication of FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum. Cancer. 2015;121:3452–4. Scholar
  53. 53.
    Winter WE III, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008;26:83–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Rose PG, Piver MS, Tsukada Y, Lau TS. Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer. 1989;64:1508–13.CrossRefPubMedGoogle Scholar
  55. 55.
    Gasparri ML, Grandi G, Bolla D, Gloor B, Imboden S, Panici PB, Mueller MD, Papadia A. Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer. J Cancer Res Clin Oncol. 2016 Jul;142(7):1509–20. Scholar
  56. 56.
    Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72(3):278–87.CrossRefPubMedGoogle Scholar
  57. 57.
    Loizzi V, Rossi C, Cormio G, Cazzolla A, Altomare D, Selvaggi L. Clinical features of hepatic metastasis in patients with ovarian cancer. Int J Gynecol Cancer. 2005;15(1):26–31.CrossRefPubMedGoogle Scholar
  58. 58.
    Kolev V, Pereira EB, Schwartz M, Sarpel U, Roayaie S, Labow D, Momeni M, Chuang L, Dottino P, Rahaman J, Zakashansky K. The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer. Int J Gynecol Cancer. 2014;24(1):70–4.CrossRefPubMedGoogle Scholar
  59. 59.
    Meredith MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol. 2003;89:16–21.CrossRefGoogle Scholar
  60. 60.
    Pekmezci S, Saribeyoglu K, Aytac E, Arvas M, Demirkiran F, Ozguroglu M. Surgery for isolated liver metastasis of ovarian cancer. Asian J Surg. 2010;30(2):83–8. Niu G, Shen C, Cui W, Li Q. Hepatic resection is safe for metachronous hepatic metastases from ovarian cancer. Cancer Biol Med. 2012;9:182–7CrossRefGoogle Scholar
  61. 61.
    Yoon SS, Jarnagin WR, Fong Y, DeMatteo RP, Barakat RR, Blumgart LH, Chi DS. Resection of recurrent ovarian or fallopian tube carcinoma involving the liver. Gynecol Oncol. 2003;91(2):383–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Chi DS, Temkin SM, Abu-Rustum NR, Sabattini P, Jarnagin W, Blumgart LH. Major hepatectomy at interval debulking for satge IV ovarian carcinoma: a case report. Gynecol Oncol. 2002;87(1):138–42. Scholar
  63. 63.
    Abood G, Bowen M, Potkul R, Aranha G, Shoup M. Hepatic resection for recurrent metastatic ovarian cancer. Am J Surg. 2008;195:370–3.CrossRefPubMedGoogle Scholar
  64. 64.
    Adam R, Hagopian EJ, Linhares M, et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg. 2002;137:1332–9. Discussion 1340.CrossRefPubMedGoogle Scholar
  65. 65.
    Elias D, et al. New perspectives in the treatment of colorectal metastases. Liver Cancer. 2016;6(1):90–8.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Eng OS, Tsang AT, Moore D, Chen C, Narayanan S, Gannon CJ, August DA, Carpizo DR, Melstrom LG. Outcomes of microwave ablation for colorectal cancer liver metastases: a single center experience. J Surg Oncol. 2015;111:410–3.CrossRefPubMedGoogle Scholar
  67. 67.
    Wang J, Liang P, Yu J, Yu MA, Liu F, Cheng Z, Yu X. Clinical outcome of ultrasound-guided percutaneous microwave ablation on colorectal liver metastases. Oncol Lett. 2014;8:323–6.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Babawale SN, Jensen TM, Frøkjær JB. Long-term survival following radiofrequency ablation of colorectal liver metastases: a retrospective study. World J Gastrointest Surg. 2015;7:33–8.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Kim KH, Yoon YS, Yu CS, Kim TW, Kim HJ, Kim PN, Ha HK, Kim JC. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc. 2011;81:25–34.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Shady W, Petre EN, Gonen M, Erinjeri JP, Brown KT, Covey AM, Alago W, Durack JC, Maybody M, Brody LA, Siegelbaum RH, D’Angelica MI, Jarnagin WR, Solomon SB, Kemeny NE, Sofocleous CT. Percutaneous radio-frequency ablation of colorectal cancer liver metastases: factors affecting outcomes-a 10-year experience at a single center. Radiology. 2016;278:601–11.CrossRefPubMedGoogle Scholar
  71. 71.
    Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg SN. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology. 2012;265:958–68.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Arie Ariche
    • 1
  • Dan Aderka
    • 2
  • Almog Ben-Yaacov
    • 3
  • Aviram Nissan
    • 3
  1. 1.Department of Hepatobiliary SurgeryThe Chaim Sheba Medical CenterTel HashomerIsrael
  2. 2.Department of OncologyThe Chaim Sheba Medical CenterTel HashomerIsrael
  3. 3.Department of General and Oncological Surgery (Surgery-C)The Chaim Sheba Medical CenterTel HashomerIsrael

Personalised recommendations